ESR1 and neoplasm: RNAseq data taken from a TCGA study of 128 patients with primary LSCC showed that patients with higher than median tumor ESR1 expression (ESR1 > 5.56) had significantly higher survival rates as compared to patients with lower tumor ESR1 expression (Fig. 5C) with p-value < 0.0001 and a hazard ratio of 0.02845.